Tarsus Pharmaceuticals (TARS)
(Delayed Data from NSDQ)
$28.24 USD
-0.01 (-0.04%)
Updated Jul 25, 2024 04:00 PM ET
After-Market: $28.22 -0.02 (-0.07%) 7:58 PM ET
3-Hold of 5 3
F Value F Growth B Momentum F VGM
Price, Consensus and EPS Surprise
TARS 28.24 -0.01(-0.04%)
Will TARS be a Portfolio Killer in July?
Zacks Investment Research is releasing its prediction for TARS based on the 1-3 month trading system that more than doubles the S&P 500.
About Price, Consensus and EPS Surprise
The Price, Consensus and EPS Surprise chart displays the company's stock price along with the consensus estimate and the EPS surprise. Zacks tracks individual sell-side analyst estimates and creates a consensus EPS estimates. The consensus estimate is the average of all the current estimates made available by brokerage analysts. Consensus estimates are more advantageous because they reduce the risk of any single analyst making an incorrect forecast. ZACKS CONSENSUS ESTIMATE = THE AVERAGE OF ALL CURRENT EPS ESTIMATES. EPS Surprise is the difference (expressed as a percentage) between the actual reported quarterly earnings per share (EPS) vs the estimated quarterly EPS. A company that reports $1.10 in actual quarterly EPS vs. $1.00 in estimated quarterly EPS would show a 10% positive EPS surprise. ((Actual EPS - Estimated EPS) / absolute Estimated EPS) *100 = EPS Surprise %.
Zacks News for TARS
Tarsus Pharmaceuticals, Inc. (TARS) Reports Q1 Loss, Tops Revenue Estimates
Does Tarsus Pharmaceuticals (TARS) Have the Potential to Rally 38.7% as Wall Street Analysts Expect?
TARS: What are Zacks experts saying now?
Zacks Private Portfolio Services
Wall Street Analysts Predict a 47.12% Upside in Tarsus Pharmaceuticals (TARS): Here's What You Should Know
Tarsus Pharmaceuticals (TARS) Upgraded to Buy: Here's Why
How Much Upside is Left in Tarsus Pharmaceuticals, Inc. (TARS)? Wall Street Analysts Think 37.91%
Other News for TARS
Interesting TARS Put And Call Options For September 20th
TARS Crosses Below Key Moving Average Level
Tarsus Pharmaceuticals (TARS) Shares Cross Below 200 DMA
Small-cap, buy-rated stocks with positive estimate revision factors - BofA
First Week of August 16th Options Trading For Tarsus Pharmaceuticals (TARS)